Sergio Cleto

1.1k total citations
36 papers, 738 citations indexed

About

Sergio Cleto is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Sergio Cleto has authored 36 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pathology and Forensic Medicine, 19 papers in Oncology and 15 papers in Neurology. Recurrent topics in Sergio Cleto's work include Lymphoma Diagnosis and Treatment (26 papers), CNS Lymphoma Diagnosis and Treatment (15 papers) and Viral-associated cancers and disorders (14 papers). Sergio Cleto is often cited by papers focused on Lymphoma Diagnosis and Treatment (26 papers), CNS Lymphoma Diagnosis and Treatment (15 papers) and Viral-associated cancers and disorders (14 papers). Sergio Cleto collaborates with scholars based in Mexico, Brazil and United States. Sergio Cleto's co-authors include Natividad Neri, Agustín Avilés, M. Jesús Nambo, Judith Huerta‐Guzmán, Alejandra Talavera, Claudia Castañeda, Serafín Delgado, Antônio Carlos Seguro, José C. Díaz‐Maqueo and Albert I. Ko and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Sergio Cleto

35 papers receiving 713 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sergio Cleto Mexico 15 477 359 130 123 91 36 738
Roberta Burnelli Italy 17 386 0.8× 226 0.6× 188 1.4× 117 1.0× 194 2.1× 40 838
Liliana Calabrese Italy 11 364 0.8× 184 0.5× 100 0.8× 108 0.9× 180 2.0× 29 743
Cathy Burton United Kingdom 16 479 1.0× 304 0.8× 95 0.7× 58 0.5× 182 2.0× 38 848
Byeong Seok Sohn South Korea 14 290 0.6× 268 0.7× 119 0.9× 253 2.1× 67 0.7× 55 673
Neil Kogut United States 18 349 0.7× 495 1.4× 83 0.6× 55 0.4× 116 1.3× 52 914
C Bayle France 14 333 0.7× 264 0.7× 203 1.6× 104 0.8× 189 2.1× 39 767
Liuyan Jiang United States 13 379 0.8× 284 0.8× 114 0.9× 71 0.6× 123 1.4× 79 666
E Salloum United States 11 330 0.7× 255 0.7× 112 0.9× 90 0.7× 158 1.7× 16 634
Glenn H. Segal United States 17 427 0.9× 266 0.7× 81 0.6× 52 0.4× 218 2.4× 33 739
Michael Roost Clausen Denmark 14 589 1.2× 536 1.5× 125 1.0× 74 0.6× 163 1.8× 79 834

Countries citing papers authored by Sergio Cleto

Since Specialization
Citations

This map shows the geographic impact of Sergio Cleto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sergio Cleto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sergio Cleto more than expected).

Fields of papers citing papers by Sergio Cleto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sergio Cleto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sergio Cleto. The network helps show where Sergio Cleto may publish in the future.

Co-authorship network of co-authors of Sergio Cleto

This figure shows the co-authorship network connecting the top 25 collaborators of Sergio Cleto. A scholar is included among the top collaborators of Sergio Cleto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sergio Cleto. Sergio Cleto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Avilés, Agustín & Sergio Cleto. (2024). Thalidomide Improve Outcomes as Maintenance Therapy in Peripheral T- Celll Lymphoma. 7(11). 1–3. 1 indexed citations
2.
Cleto, Sergio, Camila Eleutério Rodrigues, Ceila María Sant’Ana Malaque, et al.. (2016). Hemodiafiltration Decreases Serum Levels of Inflammatory Mediators in Severe Leptospirosis: A Prospective Study. PLoS ONE. 11(8). e0160010–e0160010. 13 indexed citations
3.
Pinto, Jorge, et al.. (2010). Prevalence of Primary Drug Resistance-Associated Mutations Among HIV Type 1 Vertically Infected Children in Belo Horizonte, Brazil. AIDS Research and Human Retroviruses. 26(2). 229–232. 22 indexed citations
4.
Avilés, Agustín, M. Jesús Nambo, Sergio Cleto, Natividad Neri, & Judith Huerta‐Guzmán. (2009). Rituximab and Dose-Dense Chemotherapy in Primary Testicular Lymphoma. Clinical Lymphoma & Myeloma. 9(5). 386–389. 22 indexed citations
5.
Avilés, Agustín, et al.. (2009). Rituximab and Chemotherapy in Primary Gastric Lymphoma. Cancer Biotherapy and Radiopharmaceuticals. 24(1). 25–28. 25 indexed citations
6.
Avilés, Agustín, Claudia Castañeda, Natividad Neri, et al.. (2008). Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified. Medical Oncology. 25(3). 360–364. 9 indexed citations
7.
Avilés, Agustín, M. Jesús Nambo, Natividad Neri, et al.. (2007). Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma. Medical Oncology. 24(1). 85–89. 16 indexed citations
8.
Avilés, Agustín, M. Jesús Nambo, Natividad Neri, et al.. (2007). Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Medical Oncology. 24(2). 227–230. 91 indexed citations
9.
Avilés, Agustín, M. Jesús Nambo, Natividad Neri, et al.. (2007). Interferon and Low Dose Methotrexate Improve Outcome in Refractory Mycosis Fungoides/Sézary Syndrome. Cancer Biotherapy and Radiopharmaceuticals. 22(6). 836–840. 31 indexed citations
10.
Avilés, Agustín, M. Jesús Nambo, Claudia Castañeda, et al.. (2007). Rituximab and Escalated Chemotherapy in Elderly Patients with Aggressive Diffuse Large-Cell Lymphoma: A Controlled Clinical Trial. Cancer Biotherapy and Radiopharmaceuticals. 22(2). 194–199. 15 indexed citations
11.
Avilés, Agustín, Natividad Neri, M. Jesús Nambo, Judith Huerta‐Guzmán, & Sergio Cleto. (2006). Surgery and Chemotherapy versus Chemotherapy as Treatment of High-Grade MALT Gastric Lymphoma. Medical Oncology. 23(2). 295–300. 11 indexed citations
12.
13.
Avilés, Agustín, et al.. (2005). Primary Breast Lymphoma: Results of a Controlled Clinical Trial. Oncology. 69(3). 256–260. 107 indexed citations
14.
Avilés, Agustín, M. Jesús Nambo, Natividad Neri, et al.. (2005). Biological modifiers as cytoreductive therapy before stem cell transplant in previously untreated patientswith multiple myeloma. Annals of Oncology. 16(2). 219–221. 6 indexed citations
15.
Avilés, Agustín, M. Jesús Nambo, Natividad Neri, et al.. (2004). Intensive Chemotherapy in the Treatment of Aggressive Diffuse Large B-Cell Lymphoma: Malignant Lymphoma. Medical Oncology. 21(3). 269–272. 4 indexed citations
16.
Avilés, Agustín, Sergio Cleto, Natividad Neri, et al.. (2003). Treatment of Advanced Hodgkin's Disease: EBVD versus Intensive Brief Chemotherapy. Leukemia & lymphoma. 44(8). 1361–1365. 2 indexed citations
17.
Neri, Natividad, Agustín Avilés, Sergio Cleto, et al.. (2001). Chemotherapy Plus Interferon- α 2b Versus Chemotherapy in the Treatment of Follicular Lymphoma. Journal of Hematotherapy & Stem Cell Research. 10(5). 669–674. 5 indexed citations
18.
Avilés, Agustín, et al.. (2001). Rituximab in the Treatment of Refractory Follicular Lymphoma - Six Doses Are Better Than Four. Journal of Hematotherapy & Stem Cell Research. 10(2). 313–316. 11 indexed citations
19.
Neri, Natividad, et al.. (2000). Second Lethal Events Associated with Treatment for Hodgkin's Disease: A Review of 2980 Patients Treated in a Single Mexican Institute. Leukemia & lymphoma. 39(3-4). 311–319. 11 indexed citations
20.
Avilés, Agustin, Rodolfo Alejandro, Judith Huerta‐Guzmán, Alejandra Talavera, & Sergio Cleto. (1999). Dexamethasone, All Trans Retinoic Acid and Interferon Alpha 2a in Patients with Refractory Multiple Myeloma. Cancer Biotherapy and Radiopharmaceuticals. 14(1). 23–26. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roberta Burnelli Breakdown of academic impact, for papers by Liliana Calabrese Breakdown of academic impact, for papers by Cathy Burton Breakdown of academic impact, for papers by Byeong Seok Sohn Breakdown of academic impact, for papers by Neil Kogut Breakdown of academic impact, for papers by C Bayle Breakdown of academic impact, for papers by Liuyan Jiang Breakdown of academic impact, for papers by E Salloum Breakdown of academic impact, for papers by Glenn H. Segal Breakdown of academic impact, for papers by Michael Roost Clausen
Rankless by CCL
2026